Gilead’s Trodelvy fails to meet main goal in late-stage cancer study, Top Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com

​In the overall study population, there was a higher number of deaths due to adverse events with Trodelvy, which belongs to a class of treatments known as antibody-drug conjugates, compared to chemotherapy, Gilead said., ​In the overall study population, there was a higher number of deaths due to adverse events with Trodelvy, which belongs to a class of treatments known as antibody-drug conjugates, compared to chemotherapy, Gilead said., , Read More

Leave a Reply

Your email address will not be published.